diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index ff0765e39..39c59b5ac 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -37,16 +37,22 @@ MA plans' near-universal prior authorization creates administrative friction tha ### Additional Evidence (extend) -*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-16* +*Source: 2025-05-01-nejm-semaglutide-mash-phase3-liver | Added: 2026-03-16* MASH/NASH is projected to become the leading cause of liver transplantation. GLP-1s now demonstrate efficacy across three major organ systems (cardiovascular, renal, hepatic), which strengthens the multi-indication economic case for chronic use. The 62.9% MASH resolution rate suggests GLP-1s could prevent progression to late-stage liver disease and transplantation, though the Value in Health Medicare study showed only $28M MASH savings—surprisingly small given clinical magnitude, likely because MASH progression to transplant takes decades and falls outside typical budget scoring windows. ### Additional Evidence (extend) -*Source: [[2025-12-23-cms-balance-model-glp1-obesity-coverage]] | Added: 2026-03-16* +*Source: 2025-12-23-cms-balance-model-glp1-obesity-coverage | Added: 2026-03-16* The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics. + +### Additional Evidence (challenge) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The Trump Administration Medicare deal reduces GLP-1 prices to $245/month (82% below list) with narrow eligibility targeting high-comorbidity patients (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). The $50/month out-of-pocket cap removes financial barriers for eligible Medicare beneficiaries. This pricing + targeting combination may shift the cost-effectiveness calculus: if adherence improves due to affordability AND spending is concentrated on patients where multi-organ protection generates highest savings (kidney disease, heart failure, CVD), the 'inflationary through 2035' conclusion may not hold for the Medicare population under capitated payment models. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index c8aa03417..241d62ed4 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se. + +### Additional Evidence (confirm) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The Medicare GLP-1 deal includes a $50/month out-of-pocket maximum for tirzepatide (Zepbound) starting April 2026, explicitly designed to address affordability as a discontinuation driver. The deal structure acknowledges that price, not just clinical factors, determines persistence—the policy intervention directly targets the affordability barrier identified in prior research. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json b/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json new file mode 100644 index 000000000..c420ab7be --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "narrow-eligibility-targeting-in-public-drug-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-creates-novel-policy-mechanism-bypassing-cms-rulemaking.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "narrow-eligibility-targeting-in-public-drug-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md:set_created:2026-03-16", + "manufacturer-price-concessions-in-exchange-for-coverage-expansion-creates-novel-policy-mechanism-bypassing-cms-rulemaking.md:set_created:2026-03-16" + ], + "rejections": [ + "narrow-eligibility-targeting-in-public-drug-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md:missing_attribution_extractor", + "manufacturer-price-concessions-in-exchange-for-coverage-expansion-creates-novel-policy-mechanism-bypassing-cms-rulemaking.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md b/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md index 4b112ae56..d9bc4c94d 100644 --- a/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md +++ b/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md @@ -7,9 +7,13 @@ date: 2025-11-06 domain: health secondary_domains: [internet-finance] format: news -status: unprocessed +status: enrichment priority: high tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -45,3 +49,12 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage + + +## Key Facts +- Medicare GLP-1 coverage demonstration begins July 2026 +- BALANCE Model in Medicaid launches May 2026 +- BALANCE Model in Medicare Part D launches January 2027 +- Oral Wegovy launching January 2026 at $149-$299/month +- Approximately 10% of Medicare beneficiaries expected to be eligible under comorbidity criteria +- $50/month out-of-pocket maximum for tirzepatide (Zepbound) for Medicare beneficiaries starting April 2026